FDA’s New Cell and Gene Therapy Guidance Puts CMC Readiness Back in Focus

Cell and gene therapy is moving quickly, but the latest FDA activity is a reminder that promising science still has to pass through disciplined execution.

In August 2026, FDA issued final guidance titled “Frequently Asked Questions: Developing Potential Cellular and Gene Therapy Products.” The guidance is intended to answer commonly faced questions that arise during the development of cellular and gene therapy products, including questions across regulatory review, chemistry, manufacturing, and controls, pharmacology and toxicology, clinical development, and clinical pharmacology.

That matters because cell and gene therapy products are not simple manufacturing programs. They often involve evolving processes, specialized materials, complex analytical methods, sensitive timelines, and high expectations around product quality, safety, potency, and consistency.

For life sciences companies, the message is clear: cell and gene therapy development is not only a scientific challenge. It is also a CMC, documentation, validation, quality, vendor, and readiness challenge.

Cell and Gene Therapy Development Is Moving From Promise to Execution

Cell and gene therapies have long been viewed as one of the most promising areas of life sciences. They offer potential for serious, rare, and difficult-to-treat conditions, but they also create manufacturing and operational complexity that traditional product teams may not be built to manage.

FDA’s new FAQ guidance is important because it addresses the practical questions sponsors frequently bring to the agency during development. The guidance spans multiple disciplines, but its inclusion of chemistry, manufacturing, and controls is especially relevant for teams trying to move from early development into later-stage readiness.

That is where the work becomes more demanding.

Early-stage development can tolerate a certain amount of process evolution. Later-stage development cannot rely on informal knowledge, incomplete documentation, or unclear ownership. As programs mature, teams need stronger control over process understanding, critical quality attributes, analytical methods, manufacturing changes, comparability, documentation, and readiness for regulatory review.

This is not just about getting through an FDA meeting.

It is about building a manufacturing and quality foundation that can support the product as it moves closer to patients.

CMC Flexibility Still Requires Discipline

FDA has also emphasized flexibility in CMC expectations for human cellular and gene therapy products being developed for biologics license applications. The agency’s CMC flexibilities guidance describes how FDA applies flexibility to CMC requirements for human CGT products under the BLA framework.

Flexibility is useful, but it should not be misunderstood.

It does not mean teams can treat CMC readiness as something to solve later. It means teams need to think critically about what is necessary, what is justified, what is controlled, and what evidence supports the product’s quality and manufacturing readiness.

For manufacturers, sponsors, and CDMO partners, this creates a practical execution challenge.

Teams need to define what matters most, document decisions clearly, align quality expectations, manage process changes, support validation strategy, and maintain records that can withstand scrutiny. They need to know which workstreams are mature, which are still evolving, and which gaps could become risks later.

In other words, flexibility still requires structure.

Manufacturing Readiness Is Becoming a Competitive Issue

The timing of FDA’s CGT guidance also fits a broader industry pattern: companies are investing in specialized manufacturing capacity, sterile capabilities, and advanced production networks.

Roche’s U.S. subsidiary Genentech announced plans to invest approximately $750 million in a new device fill-finish manufacturing facility at its Hillsboro, Oregon campus. The company said the project will support assembly of injectable medicines and delivery devices, double the size of the existing facility, add about 250 specialized manufacturing jobs, and provide flexible manufacturing capacity for advanced drug delivery devices.

Halo Pharma also announced that it is entering the final operational stages to activate a new sterile injectable manufacturing line at its Whippany, New Jersey facility following a $45 million investment. The company described the new capability as addressing demand from U.S.-based pharmaceutical companies seeking reliable domestic sterile manufacturing partners.

These are not cell and gene therapy examples specifically, but they reinforce a larger point that applies across life sciences: specialized manufacturing capacity is becoming a strategic priority, and readiness determines whether that capacity becomes useful.

For CGT programs, readiness is even more sensitive because the products, processes, materials, and analytical methods can be highly complex. A delay in one workstream can affect the entire development path.

The Hidden Risk Is Cross-Functional Misalignment

Cell and gene therapy programs rarely struggle because one team is not working hard enough.

They struggle because the work is deeply cross-functional.

CMC, quality, validation, engineering, automation, manufacturing, regulatory, clinical, vendors, and leadership all need to stay aligned. If those groups operate in silos, gaps can appear in the handoffs.

Examples include:

A manufacturing process changes, but the documentation trail is incomplete.

A vendor package arrives late, but the schedule still assumes qualification can start on time.

An analytical method is still evolving, but the project plan does not reflect the risk.

A process is technically working, but the evidence is not organized in a way that supports review.

A system is installed, but training, procedures, and operational handoff are not ready.

These are execution issues, not just scientific issues.

That is why CMC readiness should be managed as a project discipline. It needs visibility, ownership, documentation standards, risk tracking, and practical decision-making.

What This Means for Life Sciences Teams

FDA’s new CGT FAQ guidance is not just a regulatory document for regulatory teams. It is a signal for anyone supporting advanced therapy development that practical readiness matters.

Sponsors and manufacturers should be asking:

Are our CMC assumptions documented?

Are manufacturing changes controlled and traceable?

Are quality expectations aligned across internal and external teams?

Are vendors ready to support the next phase?

Are validation and qualification activities planned early enough?

Are project controls showing real readiness, not just activity?

Are we managing the handoff between development, manufacturing, quality, and operations?

These questions are where Persperity’s work fits.

Persperity supports complex projects in life sciences, pharmaceutical manufacturing, biotech, medical devices, CQV, C&V, project controls, validation, startup readiness, and regulated manufacturing. The focus is not simply advising from the outside. Persperity works alongside teams to help organize the work, align the stakeholders, close readiness gaps, and keep execution moving.

Cell and gene therapy may be defined by advanced science, but successful delivery depends on disciplined execution.

For advanced therapies, readiness is not a final milestone.

It is the work that makes the milestone possible.